What Will Happen to AXIM BIOTECHNOLOGIES INCORPORATED (OTCMKTS:AXIM) Next? The Stock Has Decline in Shorts

December 7, 2017 - By Migdalia James

The stock of AXIM BIOTECHNOLOGIES INCORPORATED (OTCMKTS:AXIM) registered a decrease of 35% in short interest. AXIM’s total short interest was 35,100 shares in December as published by FINRA. Its down 35% from 54,000 shares, reported previously. With 30,700 shares average volume, it will take short sellers 1 days to cover their AXIM’s short positions.

The stock decreased 0.74% or $0.05 during the last trading session, reaching $6.75. About 14,903 shares traded. AXIM Biotechnologies, Inc. (OTCMKTS:AXIM) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

AXIM Biotechnologies, Inc., a biotechnology company, focuses on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoids based products. The company has market cap of $368.31 million. It also focuses on the research, development, and production of pharmaceutical, nutraceutical, oral health, and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It currently has negative earnings. The firm was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014.

More notable recent AXIM Biotechnologies, Inc. (OTCMKTS:AXIM) news were published by: Globenewswire.com which released: “AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid …” on June 23, 2017, also Globenewswire.com with their article: “AXIM Biotech to Attend the 19th Annual BIO CEO & Investor Conference in New York” published on February 09, 2017, Globenewswire.com published: “AXIM Biotech Enters Clinical Study Agreement with University of British …” on August 02, 2017. More interesting news about AXIM Biotechnologies, Inc. (OTCMKTS:AXIM) were released by: Globenewswire.com and their article: “Axim Biotechnologies Reports Third Quarter 2017 Results” published on November 22, 2017 as well as Seekingalpha.com‘s news article titled: “AXIM Biotechnologies’ Recent Patent Does Not Offer Value To Investors” with publication date: October 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.